{"id":"W2244683785","doi":"10.1200/jco.2013.31.15_suppl.tps5103","title":"Design of the AFFINITY study: A randomized phase III study of a novel clusterin inhibitor, custirsen, plus cabazitaxel/prednisone (CbzP) versus CbzP alone as second-line chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Clusterin; Docetaxel; Cabazitaxel; Prostate cancer; Internal medicine; Oncology; Clinical endpoint; Urology; Population; Prednisone; Phases of clinical research; Enzalutamide; Chemotherapy; Surgery; Cancer; Androgen deprivation therapy; Randomized controlled trial; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004242139,0.002995262,0.003275913,0.0006887314,0.0007568424,0.001761719,0.001876393,0.002522082,0.009235111],"category_scores_gemma":[0.002407909,0.001476458,0.001639978,0.000722803,0.00218067,0.002010299,0.0007826638,0.004948244,0.001720183],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001536442,"about_ca_system_score_gemma":0.003119915,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001447681,"about_ca_topic_score_gemma":0.003233903,"domain_scores_codex":[0.9985689,0.0007169236,0.00006301066,0.000235624,0.000108065,0.0003074714],"domain_scores_gemma":[0.9982589,0.0003525341,0.0003262139,0.0001254267,0.0001104172,0.0008264959],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9492894,0.03397296,0.0009635899,0.0003356128,0.000413427,0.00006200089,0.00008106207,0.0006186537,0.004899791,0.0001757799,0.001043327,0.008144429],"study_design_scores_gemma":[0.8715168,0.1255923,0.001041955,0.00001412281,0.0002103447,0.00002698638,0.00002390719,0.0003441208,0.0004030857,0.0001420465,0.0006661049,0.00001812945],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"protocol","genre_scores_codex":[0.9473737,0.001520255,0.001554091,0.001078728,0.000787729,0.04228025,0.001832544,0.000217102,0.0033556],"genre_scores_gemma":[0.9234131,0.001757088,0.005627502,0.003231776,0.001139329,0.05585971,0.001861589,0.00008705624,0.007022778],"genre_candidate":"protocol","genre_consensus":null,"teacher_disagreement_score":0.009235111,"threshold_uncertainty_score":0.03089452,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1761461081827058,"score_gpt":0.4785932830966211,"score_spread":0.3024471749139153,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}